IDWeek 2023: 8 Research Briefs for Primary Care
Get a topline look at 8 of the many studies premiered at IDWeek that have outcomes of interest to primary care clinicians.
From antimicrobial resistance to artificial intelligence, the topics covered at IDWeek 2023, held from October 12-15, in Boston, MA, were wide ranging and many were provocative.
There were hundreds of new studies, too, on influenza, COVID-19, respiratory syncytial virus, HIV/AIDs, meningococcal disease, herpes, fungal infection, vaccines, antimicrobials, and emerging pathogens.
We chose the 8 studies that follow for the relevance of the findings to primary care practice, especially during respiratory virus season.
The authors of this first in human trial explained that the intranasal delivery method aims to replicate a natural infection and provoke a localized immune response within the nasal cavity. At present, there are no authorized live attenuated or intranasal COVID-19 vaccines.
©turhanerbas/stock.adobe.com
In adults aged ≥60 years a new study found that a single dose of RSVPreF3 OA was effective against RSV-LRTD over 2 RSV seasons, as well as against severe RSV-LRTD, and in adults with comorbidities and of advanced age.
Read more
©Kateryna_Kon/stock.adobe.com
In adults aged ≥50 years admitted to the hospital for ARI, a diagnosis of RSV was more likely among women, those who were immunocompromised, and who had traveled within the past 2 weeks.
Read more
©sudok1/stock.adobe.com
During the COVID-19 pandemic's Delta and Omicron surges, a booster dose of the mRNA-1273 vaccine provided significant additional protection against infection and particularly among adults aged 65 years and older.
Read more
©freshidea/stock.adobe.com
Older adults who received a COVID-19 and influenza vaccine in the same visit were observed to have immune responses that were noninferior to responses seen when the shots were administered sequentially. The safety profile was acceptable.
Flu ©Leigh Prather/stock.adobe.com
RSV©MargJohnsonVA/stock.adobe.com
An estimated annual reduction in infant hospitalizations of nearly 25 000 and in infant clinical encounters of 46 000 was linked to receipt of the maternal vaccine against respiratory syncytial virus in a novel modeling study.
Read more
©Dmitry Naumov/stock.adobe.com
The results of stochastic modeling provided an estimate of the impact of influenza vaccination on severe outcomes in older adults that showed significant potential reduction in CV, respiratory, and other complications and also that administering an adjuvanted or high dose vaccine could avert the majority of influenza-related hospitalizations and deaths.
Read more
©Studio Romantic/stock.adobe.com
